Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program
Business Wire•14/10/2026•08:30 ET
0
Key Highlights
- ➤$1.5 million initial option payment funds injectable hair-restoration program
- ➤Evolus can acquire 100% of program assets after clinical dataset
- ➤First-in-human clinical development anticipated after formulation work through 2027
- ➤Program does not affect previously communicated revenue or profitability outlook
Expert Statements
David Moatazedi, President and Chief Executive Officer of Evolus
“We continue to execute on the business development and pipeline strategy we have laid out, selectively pursuing opportunities that leverage our strengths in aesthetics and have the potential to expand our addressable market.”
David Moatazedi, President and Chief Executive Officer of Evolus
“This agreement gives us capital-efficient access to an attractive new category and the potential to develop a first-in-class injectable treatment for hair restoration.”
David Moatazedi, President and Chief Executive Officer of Evolus
“Importantly, the structure allows us to evaluate meaningful human clinical data before determining whether to make a larger investment in the program.”
Evolus Expands Innovation Pipeline with Novel Injectable Hair Restoration Program
Potential first-in-class injectable aesthetic procedure for hair restoration
Get started
Create a free account to read the full story.